Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?

被引：0
|
作者：
Lucien Marchand
Sophie Reffet
Stéphane Dalle
Emmanuel Disse
Julien Vouillarmet
Christine Cugnet-Anceau
Charles Thivolet
机构：
[1] Hospices Civils de Lyon,Department of Endocrinology and Diabetes
[2] Lyon-Sud Hospital,Department of Dermatology
[3] Hospices Civils de Lyon,ImmuCare (Immunology Cancer Research)
[4] Lyon-Sud Hospital,undefined
[5] Hospices Civils de Lyon,undefined
[6] Lyon 1 University,undefined
[7] CarMeN Laboratory (INSERM U1060,undefined
[8] INRA U1235,undefined
[9] Université Claude Bernard Lyon1,undefined
[10] INSA-Lyon),undefined
来源：
Acta Diabetologica | 2019年 / 56卷
关键词：
Diabetes mellitus; Fulminant diabetes; Glucose variability; Coefficient of variation for glucose; Labile diabetes; Flash glucose monitoring; FreeStyle Libre; Autoimmune diabetes; Immune checkpoint inhibitors side effects; Immunotherapy; Programmed cell death-1; Anti-PD-1; Programmed death ligand 1; Anti-PD-L1; Beta-cell pancreatic function; Alpha-cell pancreatic function; Exocrine pancreatic function;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：377 / 378
页数：1
相关论文
共 50 条
  • [21] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
    Liu, Jinhua
    Chen, Zichao
    Li, Yaqun
    Zhao, Wenjie
    Wu, JiBiao
    Zhang, Zhen
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [22] Trends in clinical development for PD-1/PD-L1 inhibitors
    Yu, Jia Xin
    Hodge, Jeffrey P.
    Oliva, Cristina
    Neftelinov, Svetoslav T.
    Hubbard-Lucey, Vanessa M.
    Tang, Jun
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (03) : 163 - 164
  • [23] Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma
    Lynch, Meghan M.
    Alexiev, Borislav A.
    Schroeder, Brett A.
    Pollack, Seth M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (12) : 1861 - 1876
  • [24] Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
    Jelinek, Tomas
    Paiva, Bruno
    Hajek, Roman
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [25] Progress on biphenyl derivatives as PD-1/PD-L1 inhibitors
    Shurong Wang
    Yuli Wang
    Hong Yan
    Medicinal Chemistry Research, 2023, 32 : 2089 - 2115
  • [26] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [27] Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1
    Guo, Jiazheng
    Yu, Fengyi
    Zhang, Kuojun
    Jiang, Sheng
    Zhang, Xiangyu
    Wang, Tianyu
    RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1096 - 1108
  • [28] Inside PD-1/PD-L1,2 with their inhibitors
    Boisgerault, Nicolas
    Bertrand, Philippe
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 256
  • [29] Soluble PD-L1 levels correlate with efficacy of PD-1/PD-L1 inhibitors in lung cancer
    Kang, Da Hyun
    Koh, Jeong Suk
    Chung, Chaeuk
    Park, Dongil
    Lee, Song-I
    Lee, Jeong Eun
    RESPIROLOGY, 2023, 28 : 99 - 99
  • [30] Machine Learning for Predicting Hyperglycemic Cases Induced by PD-1/PD-L1 Inhibitors
    Yang, Jincheng
    Li, Ning
    Lin, Weilong
    Shi, Liming
    Deng, Ming
    Tong, Qin
    Yang, Wenjing
    JOURNAL OF HEALTHCARE ENGINEERING, 2022, 2022
12345